Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinal neovascularization refers to the abnormal growth of new blood vessels in the retina. This process is central to several blinding eye diseases and involves a complex cascade of molecular and cellular events triggered by retinal ischemia or hypoxia. Key pathways and molecules involved include VEGF, Angiopoietin/Tie2, NFAT, and CHOP-HIF1α. Therapeutic strategies target these components to reduce neovascularization and improve visual outcomes.
Various, including inhibition of VEGF, modulation of Angiopoietin/Tie2 signaling, inhibition of NFAT, and modulation of ER stress response
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinal Neovascularization Pathway.